LL-37 Peptide Modulates Immune Cell Homing in Psoriasis Skin
Background
Psoriasis is a chronic, inflammatory autoimmune skin condition characterized by red, scaly patches, driven by dysregulated immune responses. Key to its pathology is the aberrant trafficking of immune cells, such as T cells and dendritic cells, from the bloodstream into the skin. While the role of various chemokines (signaling proteins that guide cell migration) in this process is well-established, the precise mechanisms by which endogenous antimicrobial peptides like LL-37 influence the skin-homing potential of peripheral immune cells in psoriasis are not fully understood.
Results
LL-37 significantly modulated the secretion of pro-inflammatory chemokines in PBMCs from psoriasis patients. Specifically, CCL20 (a chemokine crucial for recruiting T cells and dendritic cells to the skin) secretion was reduced by 45% in psoriasis patient PBMCs treated with 10 µg/mL LL-37 compared to untreated stimulated cells (p<0.001). Furthermore, CXCL8 (IL-8), another potent neutrophil chemoattractant, showed a 30% downregulation with 10 µg/mL LL-37 (p<0.01). This suppressive effect was dose-dependent, with the highest concentration of LL-37 (100 µg/mL) leading to a 60% reduction in CCL20 mRNA expression. Healthy control PBMCs exhibited minimal changes in chemokine secretion, suggesting a specific immunomodulatory effect of LL-37 within the inflammatory context of psoriasis. The most impactful finding was the 60% reduction in CCL20 gene expression in psoriasis-derived PBMCs treated with 100 µg/mL LL-37, indicating a direct transcriptional impact on a critical skin-homing chemokine.
Why It Matters
This study provides compelling evidence for LL-37's potential as a therapeutic agent for psoriasis by directly influencing the inflammatory chemokine milieu. By significantly reducing the secretion and expression of key chemokines like CCL20 and CXCL8, LL-37 could potentially limit the recruitment of pathogenic immune cells to the skin, thereby alleviating psoriatic inflammation. This mechanism offers a novel approach to target the underlying cellular trafficking in psoriasis. Future research should focus on validating these findings in relevant animal models and subsequently exploring LL-37 or its derivatives in Phase I/II human clinical trials for psoriasis treatment.